Cor Vasa 2022, 64(3):310-315 | DOI: 10.33678/cor.2022.026

(Immune Checkpoint Inhibitor Myocarditis: Current Views on Diagnosis and Treatment)

Barbora Chocholová, Petr Kuchynka, Tomáš Paleček
II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha

Immune checkpoint inhibitor (ICI) administration represents relatively new modality of cancer therapy that is increasingly used in the treatment of many malignancies, as its administration significantly improves survival of the patients. However, ICI administration may lead to several side effects, including cardiotoxic, with the most common and severe manifestation being the subject of this review, ICI-associated myocarditis. Although ICI-associated myocarditis has a low incidence, its mortality is high, reaching almost 50%. It is therefore important to be aware of the existence of ICI-associated myocarditis, its clinical manifestations, timely diagnosis, and early administration of immunosuppressive treatment with high-dose corticoids representing the first-line therapy.

Keywords: AV block, Cardiotoxicity, Immune checkpoint inhibitors, Immunosuppressive therapy, Myocarditis

Received: February 8, 2022; Revised: March 6, 2022; Accepted: March 16, 2022; Published: June 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chocholová B, Kuchynka P, Paleček T. (Immune Checkpoint Inhibitor Myocarditis: Current Views on Diagnosis and Treatment). Cor Vasa. 2022;64(3):310-315. doi: 10.33678/cor.2022.026.
Download citation

References

  1. Patel RP, Parikh R, Gunturu KS, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep 2021;23:79. Go to original source... Go to PubMed...
  2. Ederhy S, Salem J-E, Dercle L, et al. Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. Front Oncol 2021;11:640985. Go to original source... Go to PubMed...
  3. Dal'bo N, Patel R, Parikh R, et al. Cardiotoxicity of contemporary anticancer immunotherapy. Curr Treat Options Cardiovasc Med 2020;22:62. Go to original source... Go to PubMed...
  4. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98-106. Go to original source... Go to PubMed...
  5. Stein-Merlob AF, Rothberg MV, Holman P, et al. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Curr Cardiol Rep 2021;23:11. Go to original source... Go to PubMed...
  6. Johnson DB, Balko JM, Compton, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-1755. Go to original source... Go to PubMed...
  7. Pradhan R, Nautiyal A, Singh S. Diagnosis of Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Review. Int J Cardiol 2019;296:113-21. Go to original source... Go to PubMed...
  8. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-1764. Go to original source... Go to PubMed...
  9. Moslehi JJ, Salem J-E, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933. Go to original source... Go to PubMed...
  10. Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular toxicities of Immune Checkpoint Inhibitors. J Am Coll Cardiol 2019;74:1714-1727. Go to original source... Go to PubMed...
  11. Kimura T, Fukushima S, Miyashita A, et al. Myastenic crisis and polymiositis induced by one dose nivolumab. Cancer Sci 2016;107:1055-1058. Go to original source... Go to PubMed...
  12. Awadalla M, Mahmood SS, Groarke JD, et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol 2020;75:467-478. Go to original source... Go to PubMed...
  13. Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-assocaiated myocarditis. Eur Heart J 2020;41:1733-1743. Go to original source... Go to PubMed...
  14. Raikhelkar J, Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol 2019;34:303-306. Go to original source... Go to PubMed...
  15. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39:4073-4126. Go to original source... Go to PubMed...
  16. Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Curr Cardiol Rep 2021;23:11. Go to original source... Go to PubMed...
  17. Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor- -associated myocarditis. Circulation 2020;141:2031-2034. Go to original source... Go to PubMed...
  18. Coen M, Rigamonti F, Roth A, Koessler T. Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature. BMC Cancer 2017;17:394. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.